CVE-2017-18223

CVE-2017-18223 is a high-severity vulnerability in Bmc Remedy Action Request System with a CVSS 3.x base score of 8.1. It is not currently listed as actively exploited by CISA, and its EPSS exploit-prediction score is low. The underlying weakness is classified as CWE-287.

Key facts

Description

BMC Remedy AR System before 9.1 SP3, when Remedy AR Authentication is enabled, allows attackers to obtain administrative access.

Frequently asked questions

What is CVE-2017-18223?
BMC Remedy AR System before 9.1 SP3, when Remedy AR Authentication is enabled, allows attackers to obtain administrative access.
How severe is CVE-2017-18223?
CVE-2017-18223 has a CVSS 3.x base score of 8.1, rated high severity. It is exploitable over network with high attack complexity, requires no privileges and no user interaction. Impact on confidentiality is high, integrity high, and availability high.
Is CVE-2017-18223 being actively exploited?
It is not currently listed in CISA's KEV catalog. Its EPSS exploit-prediction score is 1% (58th percentile), an estimate of the probability of exploitation in the next 30 days.
What products are affected by CVE-2017-18223?
CVE-2017-18223 affects Bmc Remedy Action Request System. See the affected-products list for the exact vulnerable versions.
How do I fix CVE-2017-18223?
Review the linked vendor and NVD advisories for patched versions and mitigations, then upgrade or apply the recommended workaround. Given its high severity, prioritise patching exposed systems.
When was CVE-2017-18223 published?
CVE-2017-18223 was published on 2018-03-10 and last updated on 2026-06-17.

References

Affected products (1)

More vulnerabilities in Bmc Remedy Action Request System

All CVEs affecting Bmc Remedy Action Request System →

Other CWE-287 (Improper Authentication) vulnerabilities

Browse all CWE-287 (Improper Authentication) vulnerabilities →